Trial · NCT05595369
RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms
NCT05595369, Phase 2, Completed, Kanecia Obie Zimmerman; results first posted 2025-12-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms. Trials, record NCT05595369. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05595369
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms
- NCT number
- NCT05595369
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 963 participants, actual
- Lead sponsor
- Kanecia Obie Zimmerman
- Conditions
- Long COVID, Long Covid19
- Interventions
- Experimental: Paxlovid 25 day dosing, Experimental: Paxlovid 15 day dosing, Placebo Comparator: Control
- First posted
- 2022-10-27
- Last updated
- 2025-12-02
- Results first posted
- 2025-12-02
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Total Number of Participants Enrolled in Each Appendix | 90 days | Appendix-specific outcome measure data will be reported under the associated NCT ID. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Total Number of Participants Enrolled in Each Appendix | 90 days | Enrolled participants. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Total Number of Participants Enrolled in Each Appendix | Experimental: Paxlovid 25 Day Dosing | 323 | Participants | ||
| Total Number of Participants Enrolled in Each Appendix | Experimental: Paxlovid 15 Day Dosing | 320 | Participants | ||
| Total Number of Participants Enrolled in Each Appendix | Placebo Comparator: Control | 320 | Participants |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Experimental: Paxlovid 25 Day Dosing | 323 | |
| Overall Study | STARTED | Experimental: Paxlovid 15 Day Dosing | 320 | |
| Overall Study | STARTED | Placebo Comparator: Control | 320 | |
| Overall Study | COMPLETED | Experimental: Paxlovid 25 Day Dosing | 304 | |
| Overall Study | COMPLETED | Experimental: Paxlovid 15 Day Dosing | 297 | |
| Overall Study | COMPLETED | Placebo Comparator: Control | 304 | |
| Overall Study | NOT COMPLETED | Experimental: Paxlovid 25 Day Dosing | 19 | |
| Overall Study | NOT COMPLETED | Experimental: Paxlovid 15 Day Dosing | 23 | |
| Overall Study | NOT COMPLETED | Placebo Comparator: Control | 16 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Experimental: Paxlovid 25 Day Dosing | 0 | 321 |
| Total, all-cause mortality | Experimental: Paxlovid 15 Day Dosing | 0 | 312 |
| Total, all-cause mortality | Placebo Comparator: Control | 0 | 318 |
| Total, other adverse events | Experimental: Paxlovid 25 Day Dosing | 0 | 0 |
| Total, other adverse events | Experimental: Paxlovid 15 Day Dosing | 0 | 0 |
| Total, other adverse events | Placebo Comparator: Control | 0 | 0 |
| Total, serious adverse events | Experimental: Paxlovid 25 Day Dosing | 0 | 321 |
| Total, serious adverse events | Experimental: Paxlovid 15 Day Dosing | 0 | 312 |
| Total, serious adverse events | Placebo Comparator: Control | 0 | 318 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 42673984 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05595369
GET https://conductscience.org/api/trials/v1/NCT05595369/registered